David J Kerr, CBE, MA MD DSc FRCP (Glas & Lon) FRCGP (Hon) FMedSci Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics Head of Department of Clinical Pharmacology

David Kerr is Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics at the Department of Clinical Pharmacology, Fellow of Corpus Christi College, University of Oxford. He has worked with colleagues in Oxford to build a new Institute for Cancer Medicine and Cancer Hospital.  He has an international reputation for the treatment of and research into colorectal cancer, and is developing new approaches to cancer treatment which involve novel inhibitors of key biochemical pathways.  The quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation.  He has published more than 350 articles in peer-reviewed journals (including New England Journal of Medicine, Lancet, Nature Genetics, Nature Reviews of Cancer) and has contributed to many books on cancer.  David Kerr has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement; Chair of the National Cancer Services Collaborative, instigator of the Department of Health’s networked approach to clinical cancer research and developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”.  He is Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal, and is on the editorial board of several other journals including Nature Clinical Practice Oncology.  He has established a series of international collaborations establishing a trials network with India’s leading cancer centres INDOX (http://www.indox.org.uk/) and AfrOx (http://www.afrox.org) which aims to improve the delivery of cancer care in Sub Saharan Africa. He was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 and was recently appointed President-elect of the European Society of Medical Oncology.

Publications

Kerr, D.J., McArdle, C.S; Ledermann, J; Taylor, I; Sherlock, S.J; Schlag, P.M; Buckels, J; Mayer, D; Cain, D; Stephens, R.J. Intrahepatic arterial versus intravenous 5 fluorouracil and leucovorin for colorectal cancer liver metastases: results of a multicentre randomised trial, Lancet, 2003, 361,368-373

Neoptolemos J, Kerr DJ etal. Randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine. 350; 12. March 2004.

Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002, 359, 1555-1563

Maughan TS, James RD, Kerr D, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ on behalf of the MRC Colorectal Cancer Group Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal: a multicentre randomized trial. Lancet, 2003;361:457-464

Tomlinson et al.  A genome-wide association study identifies novel colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics. 2008

Jaeger E, Webb E, Howart K, Carvajal-Carmona L, Rowan A, Broderick P, Walther A, Spain S, Pittma A, Kemp Z, Sullivan K, Heinimann K, Lubbe, Domingo E, Barclay E, Martin L, Gorman M, Chandler I, Vijayakrishna J, Wood, Papaemmanuil E, Penegar S, Qureshi M, members of the CORGI consortium, Tenesa A, Cazier JB, Kerr D, Gray R, Peto P, Dunlop M, Thomas HH, Houlston R, Tomlinson I.  Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk.  Nature Genetics, 40: 26-28, 2007.

Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A,  Lubbe S, Spain S, Sullivan K, Fielding S, Jaeger E,  Vijayakrishnan J, Kemp Z,  Gorman M, Chandler I,  Papaemmanuil E,  Penegar S, Wood W, Sellick G, Qureshi M, Teixeira A, Domingo E, Barclay E, Martin L,  Sieber O, Kerr D, Gray R, Peto J, Cazier JP, Tomlinson I,  Houlston R. A genome-wide association study shows that common alleles of : SMAD7: influence colorectal cancer risk.  Nature Genetics 39, 1315 - 1317 (14 Oct 2007).

Ian Tomlinson, Emily Webb, Luis Carvajal-Carmona, Peter Broderick, Zoe Kemp, Sarah Spain, Steven Penegar, Ian Chandler, Maggie Gorman, Wendy Wood, Ella Barclay, Steven Lubbe, Lynn Martin, Gabrielle Sellick, Emma Jaeger, Richard Hubner, Ruth Wild, Andrew Rowan, Sarah Fielding, Kimberley Howarth, Andrew Silver, Wendy Atkin, Kenneth Muir, Richard Logan, David Kerr, Elaine Johnstone, Oliver Sieber, Richard Gray, Huw Thomas, Julian Peto, Jean-Baptiste Cazier, Richard Houlston.  A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21.  Nature Genetics 39, 984-988 (01 Aug 07)

Kerr DJ, Dunn JA, Langman MD, Smith JL, Midgley RJ, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC.  Rofecoxib and Cardiovascular adverse events in adjuvant treatment of colorectal cancer.  NEJM, 357:360-9.  July 2007

Gray, R, Barnwell J, McConkey C, Williams N and Kerr, DJ. QUASAR: a randomised study of adjuvant chemotherapy  versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group.   Lancet, 370(9604):2020-9. 2007   

 

---